查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1437507

視網膜生物製品市場，按藥物類別、適應症、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Retinal Biologics Market, By Drug Class, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2023年，視網膜生物製品市場規模為 223.45 億美元，2024年至2032年複合CAGR為 7.5%。

視網膜生物製品市場-市場動態

糖尿病和黃斑部病變盛行率上升推動市場需求

全球糖尿病和黃斑部病變的盛行率不斷上升，預計將在預測期內推動視網膜生物製品市場的發展。例如，根據糖尿病研究所基金會發表的資料，11.3%的美國人，即3,730萬人患有糖尿病。預計有 2870 萬人被診斷出患有糖尿病。全球有 860 萬人患有糖尿病，但尚未意識到自己的病情。同樣，根據CDC提供的資料，2019年40歲以上的美國人有1980萬（佔總人口的12.6%）患有年齡相關性黃斑部病變（AMD）。因此，上述統計資料預計將推動市場收入成長。

視網膜生物製劑市場 - 關鍵見解

根據研究分析師的分析，預計全球市場在預測期內（2024-2032）每年將以 7.5%左右的CAGR成長

基於藥物類別細分，VEGF-A拮抗劑領域佔市場主導地位

根據適應症細分，黃斑部病變在2023年佔據最大市場佔有率

基於配銷通路細分，醫院藥房佔據市場主導地位

依地區分類，北美是2023年的主要收入來源

視網膜生物製品市場-區隔分析：

全球視網膜生物製品市場根據藥物類別、適應症、配銷通路和地區進行細分。

根據藥物類別，市場分為兩類：TNF-a抑制劑和VEGF-A拮抗劑。 VEGF-A 拮抗劑領域在市場上佔據主導地位。該細分市場的擴張歸因於產品批准的不斷成長。例如，諾華公司透露，Beovu（R）（brolucizumab）注射液現已獲得歐盟委員會（EC）授權用於治療濕性老年黃斑部病變（AMD）。 Beovu 是第一個獲得歐盟委員會許可的抗VEGF 藥物，與阿柏西普（次要終點）相比，它顯示出更好的視網膜液（IRF/SRF）解析度，這是疾病活動的關鍵指標。

市場依適應症分為四類：糖尿病視網膜病變、黃斑部病變、葡萄膜炎等。黃斑部病變在2023年佔據最大的市場佔有率，並且由於針對黃斑部病變開發的藥物數量不斷增加以及黃斑部病變的全球發病率不斷上升，預計在預測期內將繼續保持相同的格局。例如，國家醫學圖書館2022年 9月發布的研究預測，到2040年，全球將有超過 3 億人患有年齡相關性黃斑部病變（AMD）。

根據配銷通路，市場分為三類：醫院藥房、零售藥房和網路藥房。醫院藥房在市場上佔據主導地位，並且由於各種藥物的供應，在預測期內可能會保持其主導地位。

視網膜生物製劑市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。預計北美將在預測期內引領視網膜生物製品市場。區域擴張歸因於主要市場參與者的存在及其產品的批准。例如，2023年 8月，Regeneron Pharmaceuticals 的單株抗體 Veopoz（pozelimab-bbfg）獲得 FDA 授權，用於治療 CHAPLE 病，也稱為 CD55 缺陷型蛋白丟失性腸病，治療成人及一歲以上兒童患者。此外，該公司報告指出，FDA 已授權Eylea HD（阿柏西普）注射液8 mg，這是Eylea 的高劑量形式，用於治療糖尿病視網膜病變、糖尿病黃斑水腫和濕性老年黃斑部病變（wAMD ）。此外，糖尿病盛行率的增加和黃斑部病變的盛行率預計將推動該地區的市場成長。

視網膜生物製品市場-競爭格局：

市場上的主要參與者包括F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co Inc, Bayer AG, AbbVie Inc., Janssen Biotech, Boehringer Ingelheim International GmbH, AstraZeneca plc, Fresenius SE, Teva Pharmaceuticals Industries Ltd., Novartis AG, Amgen Inc, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd. and Bristol-Myers Squibb。為了進入新市場，市場參與者不斷採取各種策略性舉措，包括創造新產品、融資和投資、併購以及其他策略夥伴關係。

最近的發展：

2023年6月，合約開發與製造組織（CDMO）Wacker Biotech與再生醫學治療公司Caeregen Therapeutics將合作開發和生產CTR-107（NoregenTM），一種用於治療視網膜相關視力喪失的新型再生療法。為了促進2024年I/II期臨床研究的啟動，Wacker Biotech作為Caeregen CTR-107的CDMO合作夥伴，將在德國哈勒的工廠生產原料藥，並在荷蘭阿姆斯特丹的工廠完成臨床試驗藥品的生產。CTR-107 是第一個獲得美國 FDA 罕見兒科疾病認定的治療家族性滲出性玻璃體視網膜病變（FEVR）的計畫。

目錄

第1章 視網膜生物製品市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘要
    • 依藥物類別分類的視網膜生物製品市場摘要
    • 按適應症分類的視網膜生物製品市場摘要
    • 依配銷通路分類的視網膜生物製品市場摘要
    • 依國家分類的視網膜生物製品市場摘要
    • 依地區分類的視網膜生物製品市場摘要
  • 競爭洞察

第3章 視網膜生物製劑主要市場趨勢

  • 視網膜生物製品市場促進因素
    • 市場促進因素的影響分析
  • 視網膜生物製品市場限制
    • 市場限制影響分析
  • 視網膜生物製品市場機會
  • 視網膜生物製品市場未來趨勢

第4章 視網膜生物製品產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 視網膜生物製劑市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 視網膜生物製品市場格局

  • 2023年視網膜生物製品市場佔有率分析
  • 細分資料：按主要製造商
    • 既有參與者分析
    • 新興參與者分析

第7章 視網膜生物製品市場 - 依藥物類別

  • 概述
    • 依藥物類別分類的細分市場佔有率分析
    • TNF-α抑制劑
    • VEGF-A拮抗劑

第8章 視網膜生物製劑市場 - 按適應症

  • 概述
    • 依適應症分類的細分市場佔有率分析
    • 糖尿病性視網膜病變
    • 黃斑部病變
    • 葡萄膜炎
    • 其他

第9章 視網膜生物製品市場 - 依配銷通路

  • 概述
    • 依配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第10章 視網膜生物製品市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美視網膜生物製品主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依藥物類別）
    • 北美市場規模和預測（依適應症）
    • 北美市場規模和預測（依配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲視網膜生物製品主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依藥物類別）
    • 歐洲市場規模與預測（依適應症）
    • 歐洲市場規模和預測（依配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區視網膜生物製劑主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依藥物類別）
    • 亞太地區市場規模與預測（依適應症）
    • 亞太地區市場規模和預測（依配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲視網膜生物製品主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依藥物類別）
    • 拉丁美洲市場規模與預測（依適應症）
    • 拉丁美洲市場規模和預測（依配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲視網膜生物製品主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依藥物類別）
    • 中東和非洲市場規模及預測（依適應症）
    • 中東和非洲市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA的其他地區

第11章 主要供應商分析 - 視網膜生物製品產業

  • 競爭儀表板
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Merck & Co Inc
    • Bayer AG
    • AbbVie Inc.
    • Janssen Biotech
    • Boehringer Ingelheim International GmbH
    • AstraZeneca plc
    • Fresenius SE
    • Teva Pharmaceuticals Industries Ltd.
    • Novartis AG
    • Amgen Inc
    • Regeneron Pharmaceuticals Inc
    • Sun Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb

第12章 360 度分析師視角

第13章 附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV2225

REPORT HIGHLIGHT

Retinal Biologics Market size was valued at USD 22,345 Million in 2023, expanding at a CAGR of 7.5% from 2024 to 2032.

Specialized therapeutic compounds called retinal biologics are used to treat a variety of retinal conditions, including diabetic retinopathy and macular degeneration. These biologics, which include proteins and antibodies produced from living things, are made to specifically target molecules or processes associated with retinal disorders. They provide more effective treatment alternatives than traditional techniques by offering tailored medicines that address the underlying processes of retinal diseases. Usually, intravitreal injections are used to give retinal biologics, which entail injecting the drug right into the eye.

Retinal Biologics Market- Market Dynamics

Increasing prevalence of diabetes and macular degeneration to propel market demand

The increasing prevalence of diabetes and macular degeneration across the globe is expected to drive the retinal biologics market over the forecast period. For instance, according to the data published by the Diabetes Research Institute Foundation, 11.3% of Americans, or 37.3 million individuals, suffer from diabetes. 28.7 million persons were projected to have been diagnosed with diabetes. 8.6 million people worldwide suffer from diabetes but are not yet aware of their condition. Similarly, as per the data provided by the CDC, 19.8 million Americans (or 12.6% of the population) over 40 had age-related macular degeneration (AMD) in 2019. Thus, the aforementioned statistics are expected to propel the revenue growth of the market.

Retinal Biologics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2024-2032)

Based on drug class segmentation, the VEGF-A Antagonist sector dominates the market

Based on indication segmentation, the macular degeneration held the largest market share in 2023

Based on distribution channel segmentation, the hospital pharmacies dominate the market

Based on region, North America was the leading revenue generator in 2023

Retinal Biologics Market- Segmentation Analysis:

The Global Retinal Biologics Market is segmented based on Drug Class, Indication, Distribution Channel, and Region.

The market is divided into two categories based on drug class: TNF-a Inhibitor and VEGF-A Antagonist. The VEGF-A Antagonist sector dominates the market. The segment expansion is attributed to the growing product approvals. For instance, Novartis disclosed that Beovu® (brolucizumab) injection is now authorized by the European Commission (EC) to treat wet age-related macular degeneration (AMD). Beovu is the first anti-VEGF medication licensed by the European Commission that has shown better resolution of retinal fluid (IRF/SRF), a crucial indicator of disease activity, in comparison to aflibercept (secondary endpoints).

The market is divided into four categories based on indication: diabetic retinopathy, macular degeneration, uveitis and others. Macular degeneration held the largest market share in 2023 and is expected to continue the same pattern during the forecast period due to the growing number of drugs being developed for macular degeneration and the condition's increasing global incidence. For instance, in September 2022 research released by the National Library of Medicine predicted that over 300 million people worldwide will have age-related macular degeneration (AMD) by the year 2040.

The market is divided into three categories based on distribution channel: hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies dominate the market and are likely to maintain their dominance during the forecast period due to the availability of various types of medication.

Retinal Biologics Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to lead the retinal biologics market during the forecast period. The regional expansion is attributed to the presence of major market players and the approvals of their products. For instance, in August 2023, Veopoz (pozelimab-bbfg), a monoclonal antibody, was authorized by the FDA by Regeneron Pharmaceuticals to treat CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, in adults and pediatric patients one year of age and older. Additionally, the firm reported that the FDA has authorized Eylea HD (aflibercept) Injection 8 mg, a high-dose form of Eylea, for the treatment of diabetic retinopathy, diabetic macular edema, and wet age-related macular degeneration (wAMD). Furthermore, the increasing prevalence of diabetes and the prevalence of macular degeneration is expected to propel the market growth in the region.

Retinal Biologics Market- Competitive Landscape:

The key players operating in the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co Inc, Bayer AG, AbbVie Inc., Janssen Biotech, Boehringer Ingelheim International GmbH, AstraZeneca plc, Fresenius SE, Teva Pharmaceuticals Industries Ltd., Novartis AG, Amgen Inc, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd. and Bristol-Myers Squibb. To obtain access to new markets, market players are continuously pursuing a variety of strategic initiatives, including the creation of new products, funding and investments, mergers and acquisitions, and other strategic partnerships.

Recent Developments:

In June 2023, Wacker Biotech, a contract development and manufacturing organization (CDMO), and Caeregen Therapeutics, a regenerative medicine therapeutics company, will work together to develop and produce CTR-107 (NoregenTM), a novel regenerative therapeutic for the treatment of retinal-related vision loss. To facilitate the start of Phase I/II clinical studies in 2024, Wacker Biotech, as Caeregen's CDMO partner for CTR-107, will create drug substance at its location in Halle, Germany, and complete clinical trial drug product manufacturing at its location in Amsterdam, the Netherlands. The first program to treat familial exudative vitreoretinopathy (FEVR) to get a Rare Pediatric Disease Designation from the US FDA is CTR-107.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RETINAL BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

F. Hoffmann-La Roche Ltd

Pfizer Inc.

Merck & Co. Inc

Bayer AG

AbbVie Inc.

Janssen Biotech

Boehringer Ingelheim International GmbH

AstraZeneca plc

Fresenius SE

Teva Pharmaceuticals Industries Ltd.

Novartis AG

Amgen Inc

Regeneron Pharmaceuticals Inc

Sun Pharmaceutical Industries Ltd.

Bristol-Myers Squibb

GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • TNF-a Inhibitor
  • VEGF-A Antagonist

GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Diabetic Retinopathy
  • Macular Degeneration
  • Uveitis
  • Others

GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL RETINAL BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Retinal Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Retinal Biologics Market Snippet by Drug Class
    • 2.1.2. Retinal Biologics Market Snippet by Indication
    • 2.1.3. Retinal Biologics Market Snippet by Distribution Channel
    • 2.1.4. Retinal Biologics Market Snippet by Country
    • 2.1.5. Retinal Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Retinal Biologics Key Market Trends

  • 3.1. Retinal Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Retinal Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Retinal Biologics Market Opportunities
  • 3.4. Retinal Biologics Market Future Trends

4. Retinal Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Retinal Biologics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Retinal Biologics Market Landscape

  • 6.1. Retinal Biologics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Retinal Biologics Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. TNF-a Inhibitor
    • 7.1.3. VEGF-A Antagonist

8. Retinal Biologics Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Diabetic Retinopathy
    • 8.1.3. Macular Degeneration
    • 8.1.4. Uveitis
    • 8.1.5. Others

9. Retinal Biologics Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Retinal Biologics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Retinal Biologics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Retinal Biologics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Retinal Biologics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Retinal Biologics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Retinal Biologics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Retinal Biologics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Merck & Co Inc
    • 11.2.4. Bayer AG
    • 11.2.5. AbbVie Inc.
    • 11.2.6. Janssen Biotech
    • 11.2.7. Boehringer Ingelheim International GmbH
    • 11.2.8. AstraZeneca plc
    • 11.2.9. Fresenius SE
    • 11.2.10. Teva Pharmaceuticals Industries Ltd.
    • 11.2.11. Novartis AG
    • 11.2.12. Amgen Inc
    • 11.2.13. Regeneron Pharmaceuticals Inc
    • 11.2.14. Sun Pharmaceutical Industries Ltd.
    • 11.2.15. Bristol-Myers Squibb

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Retinal Biologics Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Retinal Biologics Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Retinal Biologics Market: Indication Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Retinal Biologics Market, by Indication 2019-2032 (USD Million)
  • TABLE Retinal Biologics Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Retinal Biologics Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Retinal Biologics Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Retinal Biologics Market, by Region 2019-2032 (USD Million)
  • TABLE North America Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE North America Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE Europe Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE Asia Pacific Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE Latin America Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Retinal Biologics Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Retinal Biologics Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Retinal Biologics Market, by Indication, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Retinal Biologics Market, by Distribution Channel, 2019-2032 (USD Million)